Some of the key steps have included deployment of more community health workers and decentralized lab testing.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
In other mpox developments today, the WHO in an update said cases continue to decline, though Japan reported some localized spread.
The Americas reported the vast majority of new cases over the past 3 weeks—408 of 442.
Of the 85 videos analyzed, only 33% covered all content items that were highlighted in clinical practice guidelines.
Estimated 1-dose protection against symptomatic mpox was 78% after at least 14 days, ranging from 71% to 85% in sensitivity analyses.
The average time for symptom onset between successive cases (serial interval) is 8.5 days, and the time from infection to symptom onset (incubation period) is 5.6 days, new data show.
Severe complications included necrotizing (flesh-eating) skin lesions, lung dysfunction sometimes accompanied by nodules, and secondary infections and sepsis.
Experts conclude that sustained incidence of illness in a few nations, along with underreported detection of cases, was enough to maintain emergency status.
The estimated vaccine effectiveness of one subcutaneous dose of the Jynneos mpox vaccine among men in Israel is 86%.
In a related development, New York City today declared the end of its mpox outbreak, which follows 2 months of low transmission.
The WHO says cases have risen 1%, and, of 11 countries reporting increases, the largest was in Mexico.
